Richard D. Truesdell, Jr.
Lawyers
Filters
Davis Polk Advises BRP Group, Inc. on Its $229.6 Million Initial Public Offering
Davis Polk advised BRP Group, Inc. on its $229.6 million initial public offering of 16,400,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…
Aprea Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…
AbbVie Inc. €1.4 Billion Senior Notes Offering
Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…
Datadog, Inc. $648 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $648 million initial public offering by Datadog, Inc. of 24,000,000 shares of its Class A common stock. The Class A common stock…
PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering
Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…
Hamilton Lane $162.4 Million Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $162.4 million SEC-registered follow-on offering of 2,680,089 shares of Class A common stock of Hamilton Lane…
Davis Polk Advises IHS Markit Ltd. on Its $350 Million Senior Notes Reopening
Davis Polk advised IHS Markit Ltd. in connection with its SEC-registered offering of an additional $350 million aggregate principal amount of its 4.250% senior notes due 2029. The…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…
Davis Polk Advises Freeport-McMoRan Inc. on Its $1.2 Billion Notes Offering
Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.2 billion of senior notes. The offering consisted of two tranches of senior notes,…